Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as...

Area of Science:

• Hematology
• Immunology
• Transplantation Medicine

Background:

• Acute graft-versus-host disease (GVHD) is a major complication following allogeneic hematopoietic stem cell transplantation (allo-SCT).
• Mycophenolate mofetil (MMF) combined with calcineurin inhibitors is a standard prophylaxis, typically administered until day 30 post-transplant.
• The efficacy and safety of extending MMF beyond day 30 remain underexplored.

Purpose of the Study:

• To evaluate the safety and efficacy of extended MMF administration post-allo-SCT.
• To compare outcomes between patients discontinuing MMF at day 30 versus those receiving extended treatment.
• To assess the impact of extended MMF on the incidence of acute GVHD.

Main Methods:

• Retrospective analysis of patients undergoing allo-SCT.
• Two groups were compared: Group A (MMF ceased at day 30) and Group B (extended MMF based on GVHD risk factors).
• Safety was assessed by adverse events; efficacy by cumulative incidence (CI) of grade I-IV and grade II-IV acute GVHD at day 100.

Main Results:

• No severe adverse events were reported in either group.
• The CI of grade I-IV GVHD at day 100 was similar between Group A (42.3%) and Group B (12.5%).
• Group B demonstrated a significantly lower CI of grade II-IV GVHD compared to Group A.

Conclusions:

• Extended MMF administration beyond day 30 post-allo-SCT appears to be safe.
• Continuous MMF treatment may serve as an effective preemptive strategy to mitigate the development of moderate-to-severe acute GVHD.
• Individualized risk assessment can guide extended MMF regimens for enhanced GVHD prevention.